Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
12:25pm, Friday, 07'th Nov 2025
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Thursday, 06'th Nov 2025
ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Es
Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript
02:06pm, Thursday, 06'th Nov 2025
Esperion Therapeutics, Inc. ( ESPR ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Alina Venezia Sheldon Koenig - President, CEO & Director Benjamin Halladay - Chief Financia
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
08:11am, Thursday, 06'th Nov 2025
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago.
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
08:00am, Tuesday, 04'th Nov 2025
– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance –
ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientifi
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
12:55pm, Friday, 17'th Oct 2025
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering
10:01am, Thursday, 09'th Oct 2025
Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.
Esperion Announces Pricing of Public Offering of Common Stock
09:29pm, Tuesday, 07'th Oct 2025
ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commerciali
Esperion Announces Proposed Public Offering of Common Stock
04:01pm, Tuesday, 07'th Oct 2025
ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commerciali
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up
10:56am, Monday, 06'th Oct 2025
Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.
ANN ARBOR, Mich., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. and its affiliate Dr. Re
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
08:00am, Friday, 19'th Sep 2025
Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL Third Largest Global Market for Cardiovascular Prevention Represents Significant
Esperion Therapeutics, Inc. (ESPR) Presents At Cantor Global Healthcare Conference 2025 Transcript
10:17pm, Sunday, 07'th Sep 2025
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Cantor Global Healthcare Conference 2025 September 3, 2025 9:45 AM EDT Company Participants Benjamin Halladay - Chief Financial Officer Sheldon Koenig - Pres
Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
08:00am, Friday, 29'th Aug 2025
– Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence –
